GlassScriptPhysician profile
Ashley Rogers
NPI 1669868477
$1,157.17
in general payments reported to CMS, 2019-2025
12 companies · $18.09 in 2025
The $18.09 reported for 2025 was less than what a typical Neurocritical Care provider received nationally (typical 2025 total: $95.82).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $614 · 2020: $17.39 · 2022: $235 · 2023: $273 · 2025: $18.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $291.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $343.21 | 2019 | |
| Ceribell, INC. | $182.42 | 2022-2023 | Ceribell Rapid Response Eeg |
| Csl Behring | $178.44 | 2019-2023 | Kcentra |
| Medtronic, INC. | $133.63 | 2022-2025 | Cd Horizon Spinal System |
| Teva Pharmaceuticals USA, INC. | $108.60 | 2019 | |
| Integra Lifesciences Corporation | $71.97 | 2020-2022 | |
| Genentech USA, INC. | $39.60 | 2019-2023 | Phesgo, Polivy |
| Smith+Nephew, INC. | $26.79 | 2022 | |
| Merz North America, INC. | $22.49 | 2019 | |
| Lundbeck LLC | $21.83 | 2019 | |
| Stryker Corporation | $16.14 | 2022 | |
| Vertical Pharmaceuticals, LLC | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.